Citadel Advisors
LRMR icon

Citadel Advisors’s Larimar Therapeutics LRMR Stock Holding History

Citadel Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$733K Buy
240,200
+191,400
+392% +$760K ﹤0.01% 8963
2026
Q1 		$220K Buy
48,800
+31,300
+179% +$125K ﹤0.01% 11224
2025
Q4 		$66.7K Sell
17,500
-82,100
-82% -$319K ﹤0.01% 11895
2025
Q3 		$322K Buy
99,600
+39,600
+66% +$148K ﹤0.01% 10197
2025
Q2 		$173K Buy
60,000
+44,800
+295% +$104K ﹤0.01% 10818
2025
Q1 		$32.7K Sell
15,200
-15,600
-51% -$49.3K ﹤0.01% 12737
2024
Q4 		$119K Buy
30,800
+1,400
+5% +$9.24K ﹤0.01% 11204
2024
Q3 		$193K Buy
29,400
+27,100
+1,178% +$218K ﹤0.01% 10210
2024
Q2 		$16.7K Sell
2,300
-15,900
-87% -$122K ﹤0.01% 12776
2024
Q1 		$138K Buy
18,200
+18,000
+9,000% +$140K ﹤0.01% 10891
2023
Q4 		$910 Sell
200
-500
-71% -$1.69K ﹤0.01% 13918
2023
Q3 		$2.77K Sell
700
-700
-50% -$2.65K ﹤0.01% 13673
2023
Q2 		$4.38K Buy
1,400
+700
+100% +$2.86K ﹤0.01% 13601
2023
Q1 		$3.17K Buy
+700
New +$3.66K ﹤0.01% 14065
2016
Q3 		– Sell
-867
Closed -$62K – 7520
2016
Q2 		$62K Buy
+867
New +$68.5K ﹤0.01% 6355
2016
Q1 		– Sell
-192
Closed -$14K – 7444
2015
Q4 		$14K Sell
192
-75
-28% -$12K ﹤0.01% 8142
2015
Q3 		$102K Buy
+267
New +$120K ﹤0.01% 6941

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Citadel Advisors's LRMR Position: Q2 2026 in Review

Citadel Advisors increased its Larimar Therapeutics (LRMR) stake by 181% in Q2 2026, buying an estimated $3.72M and bringing the position to 1,456,825 shares worth $4.44M. The position accounts for ﹤0.01% of the portfolio, ranked #4937.

Citadel Advisors first reported a position in LRMR in Q2 2014 and has held it in 32 quarters since. The position peaked at $12.2M in Q3 2018. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Citadel Advisors held 1,456,825 shares of Larimar Therapeutics worth $4.44M as of Q2 2026.
  • Citadel Advisors bought 937,693 Larimar Therapeutics shares in Q2 2026, an estimated $3.72M.
  • Larimar Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4937 holding.
  • Citadel Advisors first reported a position in Larimar Therapeutics in Q2 2014 and has held it in 32 quarters since.
  • Citadel Advisors's Larimar Therapeutics position peaked at $12.2M in Q3 2018.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.